These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 32360532)

  • 1. Neoadjuvant chemotherapy-related platinum resistance in ovarian cancer.
    Liu J; Jiao X; Gao Q
    Drug Discov Today; 2020 Jul; 25(7):1232-1238. PubMed ID: 32360532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer.
    Luo Y; Lee M; Kim HS; Chung HH; Song YS
    Medicine (Baltimore); 2016 Sep; 95(36):e4797. PubMed ID: 27603388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
    Rauh-Hain JA; Nitschmann CC; Worley MJ; Bradford LS; Berkowitz RS; Schorge JO; Campos SM; del Carmen MG; Horowitz NS
    Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Zhang GN; Liu H; Huang JM; Wang L; Zhao JS; Li C; Mi K; Zhu Y; Cheng J; Zha X
    Gynecol Oncol; 2014 Mar; 132(3):752-7. PubMed ID: 24463159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center.
    Mueller JJ; Zhou QC; Iasonos A; O'Cearbhaill RE; Alvi FA; El Haraki A; Eriksson AG; Gardner GJ; Sonoda Y; Levine DA; Aghajanian C; Chi DS; Abu-Rustum NR; Zivanovic O
    Gynecol Oncol; 2016 Mar; 140(3):436-42. PubMed ID: 26777991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
    Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Chemotherapy Reduces the Treatment-free Interval After First-line Treatment in Patients With Advanced Ovarian Cancer.
    Ekmann-Gade AW; Hogdall CK; Engelholm SA; Fago-Olsen CL
    Anticancer Res; 2020 May; 40(5):2765-2770. PubMed ID: 32366422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
    Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
    Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of neoadjuvant chemotherapy for advanced ovarian cancer.
    Kessous R; Laskov I; Abitbol J; Bitharas J; Yasmeen A; Salvador S; Lau S; Gotlieb WH
    Gynecol Oncol; 2017 Mar; 144(3):474-479. PubMed ID: 28041690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can surgical debulking reverse platinum resistance in patients with metastatic epithelial ovarian cancer?
    Le T; Faught W; Hopkins L; Fung-Kee-Fung M
    J Obstet Gynaecol Can; 2009 Jan; 31(1):42-7. PubMed ID: 19208282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of neoadjuvant chemotherapy versus primary debulking surgery in patients with ovarian cancer: a meta-analysis.
    Lv X; Cui S; Zhang X; Ren C
    J Gynecol Oncol; 2020 Mar; 31(2):e12. PubMed ID: 31912670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Advanced ovarian cancer: primary debulking (PDS) or neoadjuvant chemotherapy (NACT) - still a debate].
    Segev Y; Gemer O; Auslender R; Lavie O
    Harefuah; 2014 Sep; 153(9):527-31, 558. PubMed ID: 25417489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum-Based Neoadjuvant Chemotherapy versus Primary Surgery in Ovarian Carcinoma International Federation of Gynecology and Obstetrics Stages IIIc and IV: A Systematic Review and Meta-Analysis.
    Xiao Y; Xie S; Zhang N; Wang J; Lv C; Guo J; Yang Q
    Gynecol Obstet Invest; 2018; 83(3):209-219. PubMed ID: 29402804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
    Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
    J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.
    Loizzi V; Leone L; Camporeale A; Resta L; Selvaggi L; Cicinelli E; Cormio G
    Oncology; 2016; 91(4):211-216. PubMed ID: 27487241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
    Morrison J; Swanton A; Collins S; Kehoe S
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005343. PubMed ID: 17943850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.
    Timmermans M; Sonke GS; van Driel WJ; Lalisang RI; Ottevanger PB; de Kroon CD; Van de Vijver KK; van der Aa MA; Kruitwagen RF
    Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():98-102. PubMed ID: 29525755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
    Rowland MR; Lesnock JL; Farris C; Kelley JL; Krivak TC
    Am J Obstet Gynecol; 2015 Jun; 212(6):763.e1-8. PubMed ID: 25644442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Primary Surgery or Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: The Debate Continues….
    Leary A; Cowan R; Chi D; Kehoe S; Nankivell M
    Am Soc Clin Oncol Educ Book; 2016; 35():153-62. PubMed ID: 27249696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.